drugset
drugset / Trial / NCT05392192

A Clinical Trial to Evaluate the Safety and Efficacy in Subjects With Chronic Cough

NCT05392192 ↗

Phase 2 Completed 51 enrolled Aldeyra Therapeutics, Inc.
RandomizedCrossoverQuadruple-blindTreatment

Summary

A Randomized, Double-Blind, Placebo-Controlled, Two-Period Crossover, Phase 2 Clinical Trial to Evaluate the Safety, Tolerability, and Efficacy of ADX-629 Administered Orally to Subjects with Chronic Cough

Timeline

Start
2022-04-07
Primary completion
2023-04-13
Completion
2023-04-13

Drugs

EvaluationDrugModalityDoseRoute
Subject ACLOPROXALAP Other / unclassified 300 mg Oral

Indications

No indication recorded.